<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292535</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000804</org_study_id>
    <nct_id>NCT04292535</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Combining Intranasal Insulin &amp; Acute Exercise</brief_title>
  <official_title>Placebo Controlled Phase II Clinical Trial: Safety and Efficacy of Combining Intranasal Insulin &amp; Acute Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if physical activity engagement alters the dose-response profile and safety of&#xD;
      administration of insulin into the intranasal mucosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a randomized placebo controlled double-blind pre-posttest design, participants will be&#xD;
      randomly assigned to receive a dose of either 0, 20, 40, 60, 80, 100, or 120 IU of NovoLog&#xD;
      insulin aspart prior to being randomized into participating in a 20 minute session of either&#xD;
      moderate-intensity aerobic exercise or a passive control condition. The efficacy of the&#xD;
      intranasal insulin for inducing alterations in cognition will be assessed using both&#xD;
      behavioral and neuroelectric measures. The safety of the protocol will be assessed using a&#xD;
      symptom questionnaire assessing common symptoms of altered blood glucose and common side&#xD;
      effects of intranasal insulin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Random allocation to a dose of intranasal insulin (0, 20, 40, 60, 80, 100, 120) Within each dose, random allocation to exercise or control activity.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind, placebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol</measure>
    <time_frame>During the 20 minute exercise/control period and the cognitive assessments.</time_frame>
    <description>The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. Burning/tingling of the nose and watering/tearing of the eyes during the nasal spray were the most cited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Manifestation of Any Symptom Following the Protocol</measure>
    <time_frame>Approximately 1 hour following the dose of intranasal insulin (~32 minutes following the end of the passive control/exercise condition; immediately following the completion of the post-test cognitive assessments)</time_frame>
    <description>The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. The most cited symptom was having a runny nose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size for Change in Behavioral Index of Inhibitory Control - RT</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a flanker test of inhibitory control. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size for Change in Behavioral Index of Inhibitory Control - Accuracy</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a flanker test of inhibitory control. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size of Change in Neuroelectric Index of Attentional Engagement - Inhibition Task</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - Inhibition Task</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size of Change in Behavioral Index of Sustained Attention - RT</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a Rapid Visual Information Processing test of sustained attention. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size of Change in Behavioral Index of Sustained Attention - Accuracy</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a Rapid Visual Information Processing test of sustained attention. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size of Change in Neuroelectric Index of Attentional Engagement - RVIP Task</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - RVIP Task</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Insulin</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>Passive Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 minute sedentary control period during which participants watched an emotionally neutral video.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo into the intranasal mucosa</intervention_name>
    <description>6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must be over the age of 18..&#xD;
&#xD;
          2. Participants must have normal or corrected-to-normal vision in order to complete the&#xD;
             cognitive task.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of consent.&#xD;
&#xD;
          2. Presence of any major neurological health issues, brain trauma, or concussion with&#xD;
             loss of consciousness assessed through a health history and demographics&#xD;
             questionnaire.&#xD;
&#xD;
          3. Type I or Type II Diabetes&#xD;
&#xD;
          4. Self-reported pregnancy&#xD;
&#xD;
          5. Currently has any type of inflammation or blockage of the nasal passageways (i.e.&#xD;
             allergies or a cold affecting the sinuses).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B Pontifex, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Kinesiology</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <results_first_submitted>March 19, 2021</results_first_submitted>
  <results_first_submitted_qc>May 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2021</results_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Matthew B. Pontifex, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Intranasal Insulin</keyword>
  <keyword>Cognition</keyword>
  <keyword>Exercise</keyword>
  <keyword>Physical Activity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing will be by request and approval of the Michigan State University Human Research Protections Program with the provision of a data-safety and sharing agreement. No individually identifiable information will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available following primary publication of the results.</ipd_time_frame>
    <ipd_access_criteria>By request</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 19, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT04292535/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the mid-Michigan area.</recruitment_details>
      <pre_assignment_details>177 individuals were assessed for eligibility. 61 individuals were excluded (58 for failing medical screening, 1 diabetic, 1 unable to exercise, 1 history of epilepsy) 116 individuals were randomized using a serial stratification approach.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Passive Control - Placebo</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P2">
          <title>Passive Control - 20 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P3">
          <title>Passive Control - 40 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P4">
          <title>Passive Control - 60 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P5">
          <title>Passive Control - 80 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P6">
          <title>Passive Control - 100 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P7">
          <title>Passive Control - 120 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P8">
          <title>Acute Exercise - Placebo</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P9">
          <title>Acute Exercise - 20 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P10">
          <title>Acute Exercise - 40 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P11">
          <title>Acute Exercise - 60 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P12">
          <title>Acute Exercise - 80 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P13">
          <title>Acute Exercise - 100 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="P14">
          <title>Acute Exercise - 120 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8">Condition stopped due to Blood Sugar Below 70 mg/dL (n = 1)</participants>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="8">Condition stopped due to Blood Sugar Below 70 mg/dL (n = 1)</participants>
                <participants group_id="P14" count="7">Condition stopped due to Blood Sugar Below 70 mg/dL (n = 1) Condition stopped due to Report of Dizziness (n = 1)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition stopped due to Blood Sugar Below 70 mg/dL</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Report of Dizziness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Equipment Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Passive Control - Placebo</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B2">
          <title>Passive Control - 20 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B3">
          <title>Passive Control - 40 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B4">
          <title>Passive Control - 60 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B5">
          <title>Passive Control - 80 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B6">
          <title>Passive Control - 100 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B7">
          <title>Passive Control - 120 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B8">
          <title>Acute Exercise - Placebo</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B9">
          <title>Acute Exercise - 20 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B10">
          <title>Acute Exercise - 40 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B11">
          <title>Acute Exercise - 60 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B12">
          <title>Acute Exercise - 80 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B13">
          <title>Acute Exercise - 100 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B14">
          <title>Acute Exercise - 120 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="7"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="9"/>
            <count group_id="B14" value="9"/>
            <count group_id="B15" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="2.0"/>
                    <measurement group_id="B2" value="20.7" spread="1.4"/>
                    <measurement group_id="B3" value="20.0" spread="0.9"/>
                    <measurement group_id="B4" value="21.9" spread="3.1"/>
                    <measurement group_id="B5" value="19.6" spread="1.3"/>
                    <measurement group_id="B6" value="20.8" spread="2.5"/>
                    <measurement group_id="B7" value="23.1" spread="3.9"/>
                    <measurement group_id="B8" value="19.8" spread="1.5"/>
                    <measurement group_id="B9" value="19.9" spread="1.5"/>
                    <measurement group_id="B10" value="21.8" spread="3.9"/>
                    <measurement group_id="B11" value="21.3" spread="3.9"/>
                    <measurement group_id="B12" value="20.2" spread="1.8"/>
                    <measurement group_id="B13" value="20.1" spread="1.4"/>
                    <measurement group_id="B14" value="20.1" spread="2.4"/>
                    <measurement group_id="B15" value="20.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.4" spread="1.9"/>
                    <measurement group_id="B2" value="14.2" spread="1.3"/>
                    <measurement group_id="B3" value="13.7" spread="1.2"/>
                    <measurement group_id="B4" value="14.4" spread="2.8"/>
                    <measurement group_id="B5" value="13.6" spread="2.7"/>
                    <measurement group_id="B6" value="13.4" spread="2.3"/>
                    <measurement group_id="B7" value="15.6" spread="2.6"/>
                    <measurement group_id="B8" value="13.0" spread="1.1"/>
                    <measurement group_id="B9" value="13.2" spread="1.9"/>
                    <measurement group_id="B10" value="15.1" spread="3.4"/>
                    <measurement group_id="B11" value="14.0" spread="2.8"/>
                    <measurement group_id="B12" value="13.7" spread="2.1"/>
                    <measurement group_id="B13" value="13.4" spread="1.4"/>
                    <measurement group_id="B14" value="13.2" spread="1.9"/>
                    <measurement group_id="B15" value="13.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WASI-II (IQ)</title>
          <description>Wechsler Abbreviated Scale of Intelligence (2nd Edition) Scores represents performance on the Vocabulary and Matrix Reasoning subtests. For each test the scores are converted to T scores. T scores on each scale are summed together. Scores range from 45 to 160 with higher values representing better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.7" spread="6.6"/>
                    <measurement group_id="B2" value="105.0" spread="7.6"/>
                    <measurement group_id="B3" value="98.3" spread="8.1"/>
                    <measurement group_id="B4" value="110.0" spread="6.4"/>
                    <measurement group_id="B5" value="113.6" spread="10.1"/>
                    <measurement group_id="B6" value="120.6" spread="12.7"/>
                    <measurement group_id="B7" value="110.7" spread="10.5"/>
                    <measurement group_id="B8" value="104.4" spread="4.3"/>
                    <measurement group_id="B9" value="110.8" spread="18.8"/>
                    <measurement group_id="B10" value="107.7" spread="8.0"/>
                    <measurement group_id="B11" value="110.8" spread="4.1"/>
                    <measurement group_id="B12" value="103.5" spread="8.7"/>
                    <measurement group_id="B13" value="108.2" spread="16.8"/>
                    <measurement group_id="B14" value="101.2" spread="17.8"/>
                    <measurement group_id="B15" value="107.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting blood glucose (mg/dL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.1" spread="6.9"/>
                    <measurement group_id="B2" value="96.0" spread="10.3"/>
                    <measurement group_id="B3" value="99.0" spread="9.3"/>
                    <measurement group_id="B4" value="91.9" spread="3.5"/>
                    <measurement group_id="B5" value="96.4" spread="6.5"/>
                    <measurement group_id="B6" value="94.4" spread="9.4"/>
                    <measurement group_id="B7" value="97.8" spread="7.3"/>
                    <measurement group_id="B8" value="92.2" spread="9.4"/>
                    <measurement group_id="B9" value="97.4" spread="7.9"/>
                    <measurement group_id="B10" value="87.1" spread="9.6"/>
                    <measurement group_id="B11" value="93.1" spread="9.3"/>
                    <measurement group_id="B12" value="96.3" spread="7.3"/>
                    <measurement group_id="B13" value="92.7" spread="9.6"/>
                    <measurement group_id="B14" value="96.0" spread="9.5"/>
                    <measurement group_id="B15" value="94.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aerobic fitness percentile</title>
          <description>Relative peak oxygen consumption (ml/kg/min) was measured using indirect calorimetry during a maximal exercise test and then converted to percentiles based upon normative data taking into account age and biological sex. Percentiles range from 3 to 97 with higher values reflecting a greater aerobic capacity.</description>
          <units>percentile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="28.8"/>
                    <measurement group_id="B2" value="26.2" spread="10.7"/>
                    <measurement group_id="B3" value="68.5" spread="12.9"/>
                    <measurement group_id="B4" value="54.5" spread="24.0"/>
                    <measurement group_id="B5" value="35.9" spread="23.1"/>
                    <measurement group_id="B6" value="53.6" spread="36.3"/>
                    <measurement group_id="B7" value="41.7" spread="26.9"/>
                    <measurement group_id="B8" value="59.2" spread="26.9"/>
                    <measurement group_id="B9" value="45.2" spread="23.7"/>
                    <measurement group_id="B10" value="48.7" spread="34.5"/>
                    <measurement group_id="B11" value="52.0" spread="28.5"/>
                    <measurement group_id="B12" value="55.8" spread="23.2"/>
                    <measurement group_id="B13" value="71.8" spread="23.2"/>
                    <measurement group_id="B14" value="28.8" spread="10.0"/>
                    <measurement group_id="B15" value="46.9" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol</title>
        <description>The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. Burning/tingling of the nose and watering/tearing of the eyes during the nasal spray were the most cited symptoms.</description>
        <time_frame>During the 20 minute exercise/control period and the cognitive assessments.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol</title>
          <description>The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. Burning/tingling of the nose and watering/tearing of the eyes during the nasal spray were the most cited symptoms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Manifestation of Any Symptom Following the Protocol</title>
        <description>The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. The most cited symptom was having a runny nose.</description>
        <time_frame>Approximately 1 hour following the dose of intranasal insulin (~32 minutes following the end of the passive control/exercise condition; immediately following the completion of the post-test cognitive assessments)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Manifestation of Any Symptom Following the Protocol</title>
          <description>The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. The most cited symptom was having a runny nose.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size for Change in Behavioral Index of Inhibitory Control - RT</title>
        <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a flanker test of inhibitory control. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size for Change in Behavioral Index of Inhibitory Control - RT</title>
          <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a flanker test of inhibitory control. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.17" upper_limit="0.09"/>
                    <measurement group_id="O2" value="-0.29" lower_limit="-0.45" upper_limit="-0.13"/>
                    <measurement group_id="O3" value="-0.54" lower_limit="-0.81" upper_limit="-0.27"/>
                    <measurement group_id="O4" value="-0.10" lower_limit="-0.38" upper_limit="0.18"/>
                    <measurement group_id="O5" value="-0.42" lower_limit="-0.61" upper_limit="-0.23"/>
                    <measurement group_id="O6" value="-0.25" lower_limit="-0.54" upper_limit="-0.03"/>
                    <measurement group_id="O7" value="-0.10" lower_limit="-0.29" upper_limit="0.09"/>
                    <measurement group_id="O8" value="-0.08" lower_limit="-0.26" upper_limit="0.10"/>
                    <measurement group_id="O9" value="-0.20" lower_limit="-0.40" upper_limit="0.01"/>
                    <measurement group_id="O10" value="-0.25" lower_limit="-0.42" upper_limit="-0.08"/>
                    <measurement group_id="O11" value="-0.33" lower_limit="-0.63" upper_limit="-0.04"/>
                    <measurement group_id="O12" value="-0.19" lower_limit="-0.42" upper_limit="0.04"/>
                    <measurement group_id="O13" value="-0.27" lower_limit="-0.57" upper_limit="0.03"/>
                    <measurement group_id="O14" value="-0.36" lower_limit="-0.55" upper_limit="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size for Change in Behavioral Index of Inhibitory Control - Accuracy</title>
        <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a flanker test of inhibitory control. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size for Change in Behavioral Index of Inhibitory Control - Accuracy</title>
          <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a flanker test of inhibitory control. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.28" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.16" lower_limit="-0.17" upper_limit="0.49"/>
                    <measurement group_id="O3" value="-0.04" lower_limit="-0.28" upper_limit="0.21"/>
                    <measurement group_id="O4" value="-0.19" lower_limit="-0.40" upper_limit="0.02"/>
                    <measurement group_id="O5" value="-0.06" lower_limit="-0.37" upper_limit="0.26"/>
                    <measurement group_id="O6" value="-0.14" lower_limit="-0.46" upper_limit="0.19"/>
                    <measurement group_id="O7" value="-0.05" lower_limit="-0.14" upper_limit="0.05"/>
                    <measurement group_id="O8" value="0.05" lower_limit="-0.23" upper_limit="0.33"/>
                    <measurement group_id="O9" value="-0.26" lower_limit="-0.74" upper_limit="0.23"/>
                    <measurement group_id="O10" value="-0.12" lower_limit="-0.51" upper_limit="0.28"/>
                    <measurement group_id="O11" value="0.06" lower_limit="-0.18" upper_limit="0.29"/>
                    <measurement group_id="O12" value="-0.01" lower_limit="-0.25" upper_limit="0.23"/>
                    <measurement group_id="O13" value="0.01" lower_limit="-0.26" upper_limit="0.27"/>
                    <measurement group_id="O14" value="-0.13" lower_limit="-0.46" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size of Change in Neuroelectric Index of Attentional Engagement - Inhibition Task</title>
        <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of Change in Neuroelectric Index of Attentional Engagement - Inhibition Task</title>
          <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.04" upper_limit="0.17"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.24" upper_limit="0.08"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-0.12" upper_limit="0.10"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.09" upper_limit="0.08"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-0.15" upper_limit="0.15"/>
                    <measurement group_id="O6" value="-0.06" lower_limit="-0.20" upper_limit="0.07"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-0.12" upper_limit="0.12"/>
                    <measurement group_id="O8" value="0.00" lower_limit="-0.09" upper_limit="0.09"/>
                    <measurement group_id="O9" value="0.00" lower_limit="-0.08" upper_limit="0.08"/>
                    <measurement group_id="O10" value="-0.04" lower_limit="-0.16" upper_limit="0.09"/>
                    <measurement group_id="O11" value="0.01" lower_limit="-0.17" upper_limit="0.19"/>
                    <measurement group_id="O12" value="-0.03" lower_limit="-0.11" upper_limit="0.04"/>
                    <measurement group_id="O13" value="0.00" lower_limit="-0.09" upper_limit="0.10"/>
                    <measurement group_id="O14" value="0.15" lower_limit="0.09" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - Inhibition Task</title>
        <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - Inhibition Task</title>
          <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" lower_limit="-0.54" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.30" upper_limit="0.19"/>
                    <measurement group_id="O3" value="0.16" lower_limit="-0.14" upper_limit="0.45"/>
                    <measurement group_id="O4" value="0.15" lower_limit="-0.28" upper_limit="0.58"/>
                    <measurement group_id="O5" value="-0.42" lower_limit="-1.00" upper_limit="0.16"/>
                    <measurement group_id="O6" value="0.06" lower_limit="-0.14" upper_limit="0.26"/>
                    <measurement group_id="O7" value="-0.05" lower_limit="-0.53" upper_limit="0.42"/>
                    <measurement group_id="O8" value="-0.21" lower_limit="-0.40" upper_limit="-0.03"/>
                    <measurement group_id="O9" value="-0.03" lower_limit="-0.37" upper_limit="0.31"/>
                    <measurement group_id="O10" value="-0.25" lower_limit="-0.52" upper_limit="0.02"/>
                    <measurement group_id="O11" value="-0.41" lower_limit="-0.98" upper_limit="0.16"/>
                    <measurement group_id="O12" value="0.12" lower_limit="-0.40" upper_limit="0.64"/>
                    <measurement group_id="O13" value="0.19" lower_limit="-0.54" upper_limit="0.93"/>
                    <measurement group_id="O14" value="0.20" lower_limit="-0.35" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size of Change in Behavioral Index of Sustained Attention - RT</title>
        <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a Rapid Visual Information Processing test of sustained attention. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of Change in Behavioral Index of Sustained Attention - RT</title>
          <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a Rapid Visual Information Processing test of sustained attention. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-0.37" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.25" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.49" upper_limit="0.19"/>
                    <measurement group_id="O4" value="-0.24" lower_limit="-0.54" upper_limit="0.06"/>
                    <measurement group_id="O5" value="-0.20" lower_limit="-0.36" upper_limit="-0.03"/>
                    <measurement group_id="O6" value="-0.22" lower_limit="-0.37" upper_limit="-0.07"/>
                    <measurement group_id="O7" value="-0.11" lower_limit="-0.37" upper_limit="0.15"/>
                    <measurement group_id="O8" value="-0.16" lower_limit="-0.29" upper_limit="-0.03"/>
                    <measurement group_id="O9" value="-0.05" lower_limit="-0.16" upper_limit="0.07"/>
                    <measurement group_id="O10" value="-0.16" lower_limit="-0.54" upper_limit="0.23"/>
                    <measurement group_id="O11" value="-0.18" lower_limit="-0.36" upper_limit="0.01"/>
                    <measurement group_id="O12" value="-0.09" lower_limit="-0.26" upper_limit="0.09"/>
                    <measurement group_id="O13" value="-0.19" lower_limit="-0.39" upper_limit="0.00"/>
                    <measurement group_id="O14" value="-0.16" lower_limit="-0.37" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size of Change in Behavioral Index of Sustained Attention - Accuracy</title>
        <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a Rapid Visual Information Processing test of sustained attention. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of Change in Behavioral Index of Sustained Attention - Accuracy</title>
          <description>The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a Rapid Visual Information Processing test of sustained attention. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.19" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.81" lower_limit="-0.10" upper_limit="1.73"/>
                    <measurement group_id="O3" value="0.05" lower_limit="-0.51" upper_limit="0.62"/>
                    <measurement group_id="O4" value="0.87" lower_limit="0.40" upper_limit="1.35"/>
                    <measurement group_id="O5" value="0.62" lower_limit="0.03" upper_limit="1.20"/>
                    <measurement group_id="O6" value="0.71" lower_limit="0.10" upper_limit="1.32"/>
                    <measurement group_id="O7" value="0.69" lower_limit="-0.13" upper_limit="1.51"/>
                    <measurement group_id="O8" value="0.54" lower_limit="0.06" upper_limit="1.02"/>
                    <measurement group_id="O9" value="0.36" lower_limit="-0.07" upper_limit="0.80"/>
                    <measurement group_id="O10" value="-0.21" lower_limit="-1.23" upper_limit="0.80"/>
                    <measurement group_id="O11" value="0.78" lower_limit="0.23" upper_limit="1.32"/>
                    <measurement group_id="O12" value="0.43" lower_limit="-0.12" upper_limit="0.98"/>
                    <measurement group_id="O13" value="0.90" lower_limit="0.33" upper_limit="1.48"/>
                    <measurement group_id="O14" value="0.60" lower_limit="-0.23" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size of Change in Neuroelectric Index of Attentional Engagement - RVIP Task</title>
        <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of Change in Neuroelectric Index of Attentional Engagement - RVIP Task</title>
          <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.27" upper_limit="0.23"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.21" upper_limit="0.03"/>
                    <measurement group_id="O3" value="0.04" lower_limit="-0.20" upper_limit="0.29"/>
                    <measurement group_id="O4" value="0.23" lower_limit="0.02" upper_limit="0.45"/>
                    <measurement group_id="O5" value="0.02" lower_limit="-0.17" upper_limit="0.21"/>
                    <measurement group_id="O6" value="0.16" lower_limit="0.03" upper_limit="0.28"/>
                    <measurement group_id="O7" value="0.08" lower_limit="-0.15" upper_limit="0.31"/>
                    <measurement group_id="O8" value="0.03" lower_limit="-0.17" upper_limit="0.24"/>
                    <measurement group_id="O9" value="0.02" lower_limit="-0.18" upper_limit="0.22"/>
                    <measurement group_id="O10" value="0.02" lower_limit="-0.15" upper_limit="0.20"/>
                    <measurement group_id="O11" value="0.18" lower_limit="0.00" upper_limit="0.36"/>
                    <measurement group_id="O12" value="0.04" lower_limit="-0.25" upper_limit="0.33"/>
                    <measurement group_id="O13" value="-0.03" lower_limit="-0.19" upper_limit="0.14"/>
                    <measurement group_id="O14" value="-0.06" lower_limit="-0.35" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - RVIP Task</title>
        <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
        <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Passive Control - Placebo</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O2">
            <title>Passive Control - 20 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O3">
            <title>Passive Control - 40 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O4">
            <title>Passive Control - 60 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O5">
            <title>Passive Control - 80 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O6">
            <title>Passive Control - 100 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O7">
            <title>Passive Control - 120 IU</title>
            <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O8">
            <title>Acute Exercise - Placebo</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O9">
            <title>Acute Exercise - 20 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O10">
            <title>Acute Exercise - 40 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O11">
            <title>Acute Exercise - 60 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O12">
            <title>Acute Exercise - 80 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O13">
            <title>Acute Exercise - 100 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
          <group group_id="O14">
            <title>Acute Exercise - 120 IU</title>
            <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - RVIP Task</title>
          <description>The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis.&#xD;
Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups.</description>
          <units>cohens d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-0.32" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.26" upper_limit="0.14"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-0.77" upper_limit="0.61"/>
                    <measurement group_id="O4" value="-0.09" lower_limit="-0.29" upper_limit="0.11"/>
                    <measurement group_id="O5" value="0.26" lower_limit="-0.43" upper_limit="0.96"/>
                    <measurement group_id="O6" value="0.25" lower_limit="-0.36" upper_limit="0.86"/>
                    <measurement group_id="O7" value="-0.10" lower_limit="-0.48" upper_limit="0.29"/>
                    <measurement group_id="O8" value="-0.03" lower_limit="-0.33" upper_limit="0.27"/>
                    <measurement group_id="O9" value="0.34" lower_limit="-0.15" upper_limit="0.83"/>
                    <measurement group_id="O10" value="0.00" lower_limit="-0.22" upper_limit="0.21"/>
                    <measurement group_id="O11" value="0.04" lower_limit="-0.30" upper_limit="0.37"/>
                    <measurement group_id="O12" value="0.05" lower_limit="-0.30" upper_limit="0.40"/>
                    <measurement group_id="O13" value="0.10" lower_limit="-0.36" upper_limit="0.57"/>
                    <measurement group_id="O14" value="0.05" lower_limit="-0.37" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Only during the two 90 minute sessions.</time_frame>
      <desc>The clinicaltrials.gov definitions for adverse events was used. Indications of onset of an issue related to hypoglycemia were stopping criteria for the study protocol and are considered herein as Non serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Passive Control - Placebo</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E2">
          <title>Passive Control - 20 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E3">
          <title>Passive Control - 40 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E4">
          <title>Passive Control - 60 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E5">
          <title>Passive Control - 80 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E6">
          <title>Passive Control - 100 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E7">
          <title>Passive Control - 120 IU</title>
          <description>20 minute sedentary control period during which participants watched an emotionally neutral video.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E8">
          <title>Acute Exercise - Placebo</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E9">
          <title>Acute Exercise - 20 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E10">
          <title>Acute Exercise - 40 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E11">
          <title>Acute Exercise - 60 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E12">
          <title>Acute Exercise - 80 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E13">
          <title>Acute Exercise - 100 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
        <group group_id="E14">
          <title>Acute Exercise - 120 IU</title>
          <description>20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate.&#xD;
120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemic event</sub_title>
                <description>Blood sugar fell below 70 mg/Dl or exhibited Dizziness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As the present investigation was a Phase II Clinical Trial, the research design was not sufficiently powered for hypothesis testing. Given the potential risk of combining exercise with intranasal insulin the present investigation utilized a sample of healthy, non-diabetic, fasted college-aged adults to limit the potential for a serious adverse event.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Matthew B. Pontifex</name_or_title>
      <organization>Michigan State University</organization>
      <phone>517-432-5105</phone>
      <email>pontifex@msu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

